Skip to main content
. 2019 Dec 30;9(1):89. doi: 10.3390/cells9010089

Figure 5.

Figure 5

TNS3 controls the activity of ITGβ1. (A) Total and active ITGβ1 levels were 80.9% and 80.5%, respectively, in siControl-treated TMSCs, and were significantly reduced to 51.2% and 49.2%, respectively, following siTNS3 treatment by flow cytometry. (B) After siTNS3 treatment, both nucleus (blue) and ITGβ1 (red) decreased. Confocal microscopy (×400). (C) When TNS3 was inhibited, talin, kindlin were unchanged, and AMPK was reduced in Western blot analysis. (D) Photomicrographs acquired after siTNS3 transfection showed reduced cell numbers, but no morphologic changes in transfected cells compared to the control (left panel). In the MTT assay, the siITGβ1-treated group showed lower proliferation rates compared to the control during the whole observation period; these differences were significant on day 3. (E) In Western blot analysis, the level of SOX2 was decreased, whereas those of p16, p19, p21 were increased after siITGβ1 treatment. When ITGβ1 was inhibited, the pFAK, pERK,p JNK,pPI3K,pAkt levels were all decreased. * p < 0.05 compared to the control. n = 4. Columns and error bars represent the mean ± standard deviation.